Nanopharm Ltd, an Aptar Pharma Company

Meet Robert Bootle, one of our Associate Managers of Pharmaceutical Development. In this interview, we talk to Rob, a seasoned inhalation expert with a Masters in Chemistry.  Rob serves as an Associate Manager at Nanopharm Ltd, an Aptar Pharma Company, leveraging his expertise to manage a team of scientists to deliver next-generation inhaled and nasal drug delivery solutions for our customers, helping them to advance new medicines across various therapy areas. Read the full article below ⬇️ https://lnkd.in/eSiJicGa #InhalationScience #DrugDelivery #PharmaInnovation #AnalyticalChemistry #Biotech #PharmaLeadership #InhaledTherapies

One of the biggest challenges in drug delivery is effectively targeting the brain for CNS disorders. While you can reach the brain through traditional routes of administration, nasal delivery may offer a unique and efficient pathway. By leveraging the nose-to-brain route, research suggests that the drug can bypass the blood brain barrier (BBB) and enable faster, more direct drug absorption, potentially transforming treatments for neurological conditions. At Nanopharm, we specialize in optimizing nasal drug delivery through offering formulation development, device selection and analytical services to unlock new possibilities, utilizing our Simhalation™ PBPK modelling platform to help further derisk clinical studies. 💡 Want to learn more? Meet us at the 3rd Nasal Formulation & Delivery Summit in Boston (April 1-3) to discuss the future of nose-to-brain drug delivery. #Nanopharm #NasalDrugDelivery #DrugDevelopment #PharmaceuticalScience #OINDP #NasalPowder #NasalSpray #NoseToBrain

Meet Steven Kim – Nanopharm’s Account Manager Steven joined the Aptar family in 2022 and moved into Nanopharm Ltd, an Aptar Pharma Company in 2023, bringing over eight years of experience in sales and marketing within the contract testing laboratory field. His background as a bench chemist and extractions technician in both environmental and pharmaceutical analytical services gives him a deep understanding of the science behind what we do and can help join the dots to what our customers need. At Nanopharm, Steven is dedicated to supporting clients throughout their journey, ensuring seamless collaboration and delivering innovative solutions in inhalation and nasal drug development. His primary focus is on vaccines and anti-infective nasal drug delivery and products for allergic rhinitis. Get in touch with Steven at info@nanopharm.co.uk to learn how Nanopharm can support your next project. #Nanopharm #PharmaDevelopment #InhalationScience #BusinessDevelopment #DrugDelivery

Nanopharm is attending the 3rd Nasal Formulation & Delivery Summit in Boston! We’re excited to join industry leaders at this key event, taking place April 1st-3rd, to discuss the latest advancements in nasal drug delivery. Representing Nanopharm will be Klara Fisken, who looks forward to connecting with fellow experts and exploring innovations in systemic nasal drug delivery, nose-to-brain (N2B) therapies, and emergency treatments and Steven Kim who is ready to discuss nasal delivery for vaccines and anti-infective drugs and treatments for allergic rhinitis. If you’re attending, please reach out to Klara or Steven at info@nanopharm.co.uk - we’d love to connect. #Nanopharm #NasalDrugDelivery #NoseToBrain #PharmaInnovation #DrugDelivery #InhalationScience

Welcome to the Team, Klara Fisken We’re excited to introduce Klara Fisken, our new Business Development Manager at Nanopharm! With a strong background in CDMOs & CROs, Klara brings valuable expertise in dry powder dosage forms and enabling technologies. Her focus? Systemic Nasal Drug Delivery (SNDD), including CNS therapies and emergency drugs. She’ll be working closely with our clients to onboard new projects and support them throughout their journey with Nanopharm. 📩 Get in touch with Klara at info@nanopharm.co.uk to discuss how Nanopharm can support your project. #Nanopharm #BusinessDevelopment #InhalationScience #NasalDrugDelivery

Nanopharm Named OINDP Developer of the Year! We’re thrilled to announce that Nanopharm has won Global Health & Pharma’s Global Excellence Award for OINDP Developer of the Year 2024! 🎉 This prestigious award recognizes our commitment to innovation in inhalation science, setting new standards in bioequivalence and pioneering cutting-edge solutions for inhaled and nasal drug development. A huge thank you to our team, partners, and clients for being part of this journey! #Nanopharm #GlobalExcellenceAwards #OINDP #InhalationScience #PharmaInnovation

Welcome to the Team, Kiran S.! We’re thrilled to introduce Kiran Sarai, part of our Business Development team at Nanopharm! With a background in Biochemistry and Biological Sciences, Kiran previously worked in business development at MedPharm CDMO, specializing in topical pharmaceuticals. At Nanopharm, she’ll be supporting new client projects and managing relationships throughout their journey with us, with a particular emphasis on Dry Powder Inhalers (DPI) and Non-Propellant Liquid Inhalers (NPLIs). 📩 Get in touch with Kiran at info@nanopharm.co.uk to explore how we can support your project. #Nanopharm #BusinessDevelopment #InhalationScience #DPI #NPLI

From global hubs to cutting-edge conversations—Nanopharm was everywhere last year, attending 20+ conferences worldwide! This year, we’re raising the bar even higher. We’re dedicated to staying at the forefront of inhalation science, connecting with industry leaders, and driving innovation in OINDP development. Make sure you’re following us to see which conferences we’re attending this year - we’ll be updating our page regularly - https://lnkd.in/eug2h_VR #Nanopharm #PharmaConferences #InhalationScience #OINDP #Networking #PharmaInnovation

Meet Nanopharm Ltd, an Aptar Pharma Company at SMI.London We are pleased to welcome Nanopharm as an exhibitor at SMI.London 2025. Come and meet Nanopharm on 25 June 2025 in London. Register here to attend: SMI.London

Interested in attending RDD Europe 2025, co-organized by RDD Online® and Aptar Pharma? Be sure to register by February 28th to benefit from the Early Bird rate. At RDD 2025, you are guaranteed three days full of scientific presentations, posters, workshops and networking opportunities around all aspects of pulmonary and nasal drug delivery. Don’t miss out! To register as a delegate, visit https://ow.ly/gFmt50UX2C3. #RDDEurope #AptarPharma #Respiratory #DrugDelivery #RDD2025 #Nasal #Inhalation #Pulmonary